39th week of 2009 patent applcation highlights part 44 |
Patent application number | Title | Published |
20090239724 | EXERCISE MAT - A mat that can be used for the practice of yoga includes a curve-shaped design and strategically placed stitch markings to assist the user in producing a properly aligned position with each yoga pose or yoga posture. Both the shape enhancements and stitch markings can help create a technological and functional mat to help both novice and expert practitioners achieve better performance in their yoga practice. | 2009-09-24 |
20090239725 | METHOD AND SYSTEM FOR ASSOCIATING AN INSERT WITH A CARTON - To associate a paper insert with a carton, a first identifier (such as identifying indicia) is read from the insert and a second identifier is read from the carton blank. A determination is made whether the first identifier and the second identifier indicate the paper insert is properly matched with the carton blank. If yes, the paper insert is affixed to the carton blank and the carton blank is folded around the insert and its margins glued together to form a flat sleeve surrounding the insert. If no, the mismatch may be indicated. | 2009-09-24 |
20090239726 | SYSTEM AND APPARATUS FOR ERECTING CASES - A case forming apparatus that erects cases from knocked-down case blanks includes a first jaw and a plurality of stabilizer bars each having a first end mounted to the first jaw. The stabilizer bars are spaced radially from each other and form concentric segments of circles centered on a pivotal axis. A moveable second jaw is mounted for movement on the pivotal axis relative to the first jaw between an open position where the moveable second jaw is substantially perpendicular to the first jaw and a closed position where the moveable second jaw is substantially parallel to the first jaw. The moveable second jaw includes openings through which the stabilizer bars pass as the moveable second jaw moves between the open and closed positions. At least one of the stabilizer bars has a cross-sectional width that varies over at least one-third of a cross-sectional height of the at least one stabilizer bar. | 2009-09-24 |
20090239727 | Apparatus and method for cutting and folding printed products - An apparatus for cutting and folding printed products is provided. The apparatus includes a perforator, a first cutting device creating first slits in the web, a second cutting device creating second slits in the web longitudinally offset from the first slits so as to form a signature with a staggered edge, and a folder delta-folding the signature so that the staggered edge engages slots in the signature, the slots created by the perforator. A method of folding a printed product and a signature are also provided. Lead edges can be more easily prevented from dislodging and dog-earing and skewing can be minimized. | 2009-09-24 |
20090239728 | Device for the Folding of Flexible Material - A device for the folding of flexible material in the form of a continuous strip ( | 2009-09-24 |
20090239729 | CENTRIFUGAL SEPARATOR - A centrifugal separator includes a sample line and a rotating apparatus portion including a rotor that has a rotor chamber. The centrifugal separator centrifugally separates a sample by supplying the sample from the sample line into the rotor and driving to rotate the rotor in the rotor chamber and discharges the centrifugally separated sample from the rotor via the sample line. The centrifugal separator includes a sterilizing apparatus for sterilizing at least a portion with which the sample is brought into contact by making a sterilizing fluid flow through the sample line. | 2009-09-24 |
20090239730 | CIRCUMFERENTIALLY DRIVEN CONTINUOUS FLOW CENTRIFUGE - A centrifuge ( | 2009-09-24 |
20090239731 | WATER-SOLUBLE GLASS COMPOSITION - A zinc and bismuth containing, water-soluble glass composition comprising from 10 to 75 mole % P | 2009-09-24 |
20090239732 | Optical component quartz glass - Starting from an optical component of quartz glass for transmitting ultraviolet radiation of a wavelength between 190 nm and 250 nm, with a glass structure essentially without oxygen defects, a hydrogen content ranging from 0.1×10 | 2009-09-24 |
20090239733 | Methods of heat-treating soda-lime glass substrates and heat-treated soda-lime glass substrates formed using the same - A soda-lime glass substrate formed through a heat-treatment method has an absorption coefficient ranging from about 0.15 λ,W/m·K to about 0.54 λ,W/m·K, and a free path length ranging from about 0.12 cm to about 0.24 cm. The heat-treated soda-lime glass substrate is formed by heating for a selected time at a pre-specified maximum temperature of about 270° C. to about 330° C. so as to remove thermally induced residual deformations from the substrate and then the substrate is slowly cooled so as to substantially avoid reintroducing thermally induced residual deformations into the cooling substrate. Thus, the soda-lime glass substrate is transformed to one at or close to its contraction saturation point. This allows the heat-treated soda-lime glass substrate to serve in a practical way as a substrate of a flat display panel. | 2009-09-24 |
20090239734 | CORDIERITE CERAMIC AND METHOD OF PRODUCING THE SAME - A method of producing cordierite ceramic where the degree of stacking faults and the particle diameter of kaolinite used as a component of a cordierite-forming raw material are appropriately adjusted so that microcracks having an average width of 0.3 μm or more are introduced into the resulting cordierite ceramic to produce a high-quality cordierite ceramic that includes a cordierite crystal oriented in a specific direction and has a porosity of 25% or more and a coefficient of thermal expansion of 0.30×10 | 2009-09-24 |
20090239735 | Method for treating flue gas catalysts - A method for treating a catalyst base that comprises a contact area of porous material. A fluid, such as a flue gas stream, can be conducted along the contact area. A catalytically relevant substance is introduced into pores of the catalyst base using a transport fluid and remains on pore wall areas after removal of the transport fluid. The introduction is carried out such that an amount of the catalytically relevant substance relative to the surface remains on the pore wall areas as a function of location within the pore and decreases within the pore after exceeding a specific pore depth. A blocking fluid can first be introduced into pore regions beyond the specific pore depth, thus blocking these regions when transport fluid containing the catalytically relevant substance is introduced. | 2009-09-24 |
20090239736 | PROCESSES FOR REGENERATING SULFUR-POISONED, RUTHENIUM AND/OR RUTHENIUM COMPOUND-CONTAINING CATALYSTS - Processes comprising: providing a catalyst comprising a catalytic component selected from the group consisting of ruthenium, ruthenium compounds, and combinations thereof, wherein the catalyst is sulfur-poisoned with one or more sulfur compounds; and treating the catalyst with a gas stream comprising a hydrogen halide under nonoxidative conditions such that the catalyst is regenerated. | 2009-09-24 |
20090239737 | Method Of Synthesizing Aluminophosphate And Silicoaluminophosphate Molecular Sieves - In a method of synthesizing an aluminophosphate or silicoaluminophosphate molecular sieve, a synthesis mixture is prepared by mixing a plurality of starting materials including at least a source of water, a source of phosphorus, a source of aluminum, optionally, a source of silicon and, and at least one organic directing agent for directing the formation of said molecular sieve. The starting materials are maintained at a temperature between 25° C. and 50° C., preferably between 30° C. and 45° C., during the mixing and until preparation of the starting mixture is complete, whereafter the synthesis mixture is heated to a crystallization temperature between about 100° C. and about 350° C. until crystals of the molecular sieve are produced. When crystallization is complete, the molecular sieve is recovered. | 2009-09-24 |
20090239738 | Titanium Oxide Photocatalyst, Process For Producing The Same And Application - Titanium oxide-based photocatalysts which contain a metal halide in titanium oxide and which are prepared from titanium oxide and/or its precursor, which may optionally be heat treated, by contact with a reactive gas containing a metal halide of the formula MX | 2009-09-24 |
20090239739 | CATALYST, EXHAUST GAS PURIFYING CATALYST, AND METHOD OF PRODUCING THE CATALYST - A catalyst | 2009-09-24 |
20090239740 | HONEYCOMB STRUCTURE - A honeycomb structure includes a plurality of honeycomb fired bodies. Each of the plurality of honeycomb fired bodies has a longitudinal direction and cell walls extending along the longitudinal direction to define cells. An adhesive layer is provided between the plurality of honeycomb fired bodies to connect the plurality of honeycomb fired bodies so that each longitudinal direction is substantially in parallel with each other. The plurality of honeycomb fired bodies include at least one center-portion honeycomb fired body located at a center portion of the honeycomb structure and at least one periphery honeycomb fired body surrounding the center-portion honeycomb fired body to form a peripheral face of the honeycomb structure. The periphery honeycomb fired body includes contact faces contacting the adhesive layer. At least one of the contact faces has irregularities. | 2009-09-24 |
20090239741 | FORMED ARTICLE OF CORDIERITE AND METHOD FOR MANUFACTURING THE FORMED ARTICLE - A formed article is made of cordierite. The cordierite has a plurality of domains and a plurality of crystal grains placed in each domain to form a domain structure. The crystal grains in each domain are substantially aligned in the same direction, and an average size of the domains ranges from 40 μm to 150 μm. The article of cordierite is formed in a honeycomb structure having a plurality of cell walls arranged in a honeycomb form, and a plurality of cells divided by the cell walls are formed. The article of cordierite has a porosity ranging from 36% to 38%, a coefficient of linear thermal expansion equal to or lower than 0.2×10 | 2009-09-24 |
20090239742 | LONG-LIVED HIGH VOLUMETRIC ACTIVITY PHOTOCATALYSTS - The present disclosure relates to nanocrystalline titanium dioxide (TiO | 2009-09-24 |
20090239743 | CATALYST COMPOSITION, ITS PREPARATION AND USE - An unsupported catalyst composition which comprises one or more Group VIb metals, one or more Group VIII metals, and a refractory oxide material which comprises 50 wt % or more titania, on oxide basis, which is prepared by precipitation techniques, finds use in the hydroprocessing of hydrocarbonaceous feedstocks. | 2009-09-24 |
20090239744 | HONEYCOMB STRUCTURE AND METHOD FOR MANUFACTURING HONEYCOMB STRUCTURE - A honeycomb structure includes a plurality of honeycomb fired bodies combined with one another. The honeycomb fired bodies include a center-portion honeycomb fired body located in a center portion in a cross section perpendicular to a longitudinal direction and a peripheral-portion honeycomb fired body located in a peripheral portion in the cross section. The center-portion honeycomb fired body has a substantially rectangular cross-sectional shape and has an area from about 2500 mm | 2009-09-24 |
20090239745 | CATALYST FOR PURIFYING EXHAUST GAS - To improve a CO conversion in stoichiometry-lean atmosphere, and additionally to prevent the rise of pressure loss. | 2009-09-24 |
20090239746 | THERMOSENSITIVE RECORDING MATERIAL - A thermosensitive recording material including a polypropylene film support, a thermosensitive recording layer, a protective layer and a back layer, where the thermosensitive recording layer and the protective layer are disposed on a surface of the polypropylene film support, and the back layer is disposed on another surface of the polypropylene film support, where the back layer is a coated layer of a coating liquid containing a self-crosslinking resin emulsion, which contains a combination of at least one selected from a carbonyl group-containing acrylic resin having a Tg of 16° C. or lower and a copolymer polyester resin having a Tg of 16° C. or lower and a hydrazine derivative having a hydrazine residual group, and a quaternary ammonium polymer antistatic agent. | 2009-09-24 |
20090239747 | HEAT RESISTANCE IMPROVER AND REVERSIBLE THERMOSENSITIVE RECORDING MEDIUM - A heat resistance improver including a heat resistance improving component which has a benzotriazole skeleton having an electron attractive group and a reactive aliphatic hydroxyl group or a reactive aliphatic mercapto group, wherein the heat resistance improver is used in a reversible thermosensitive recording medium. | 2009-09-24 |
20090239748 | Fungicidal Mixtures Based on 2,5-Disubstituted N-Biphenylpyrazolcarboxamides - The present invention relates to fungicidal mixtures comprising, as active components, | 2009-09-24 |
20090239749 | Biocidal compositions - The invention provides a solvent-free biocidal composition of improved efficacy comprising at least one water insoluble biocide (preferably a herbicide) and a water-soluble carrier material, wherein the water-insoluble biocide is dispersed through the carrier material in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm. The invention also provides a process which comprises spray drying a solution of the biocide and a solution of a water-soluble carrier to obtain a solvent free dispersion of the biocide in the carrier, which, when dissolved in water, produces a nano-disperse biocide. The invention also provides an aqueous dispersion of a water insoluble biocide and a water-soluble carrier obtained by the dispersion of the composition of the solvent free composition in water. | 2009-09-24 |
20090239750 | EMULSION COMPOSITION - There is provided an emulsion composition useful as a preparation containing an active agrochemical compound. The emulsion composition essentially consisting of 0.5 to 25% by weight of one or a plurality of hydrophobic active agrochemical compounds; 5 to 15% by weight of one or a plurality of surfactants; 2 to 60% by weight of one or a plurality of aromatic hydrocarbon solvents; 2 to 60% by weight of propylene glycol diacetate; 12 to 90% by weight of 1,3-dimethyl-2-imidazolidinone; and 0 to 5% by weight of one or a plurality of formulation auxiliaries, wherein a weight ratio of 1,3-dimethyl-2-imidazolidinone and the aromatic hydrocarbon solvent(s) is 1:0.03 to 1:2.0, and a weight ratio of 1,3-dimethyl-2-imidazolidinone and propylene glycol diacetate is 1:0.03 to 1:2.0. | 2009-09-24 |
20090239751 | ELECTRICAL CONNECTION STRUCTURE FOR A SUPERCONDUCTIVE ELEMENT - The invention relates to a high voltage electrical connection structure for a superconductive element cooled by a cryogenic fluid in a cryostat and connected to an electrical bushing that passes through at least one enclosure at ambient temperature, said bushing comprising a central conductor having its top end connected by means of a connection arrangement to a connection part extending to outside the enclosure at ambient temperature and passing through a top wall of said enclosure, said central conductor being surrounded over the major fraction of the length by an electrically insulating sheath fastened rigidly to the bottom wall of said enclosure at ambient temperature. According to the invention, said connection arrangement comprises a conductive part mounted on said top end at ambient temperature of the central conductor and a plurality of deformable conductive elements connected to said conductive part and to said connection part, said conductive part having a cylindrical wall surrounding said conductive elements and forming a screen relative to the electric field. | 2009-09-24 |
20090239752 | Superconducting device, fabrication method thereof, and filter adjusting method - A superconducting device comprises a dielectric substrate, and a plane-figure type resonator pattern made of a superconductive material and formed on a first face of the dielectric substrate. The resonator pattern has a notch at least a portion of which is round. | 2009-09-24 |
20090239753 | METHOD OF MANUFACTURING SUPERCONDUCTING THIN FILM MATERIAL, SUPERCONDUCTING DEVICE AND SUPERCONDUCTING THIN FILM MATERIAL - A method of manufacturing a superconducting thin film material includes a vapor phase step of forming a superconducting layer by a vapor phase method and a liquid phase step of forming a superconducting layer by a liquid phase method so that the latter superconducting layer is in contact with the former superconducting layer. Preferably, the method further includes the step of forming an intermediate layer between the former superconducting layer and a metal substrate. The metal substrate is made of a metal, and preferably the intermediate layer is made of an oxide having a crystal structure of any of rock type, perovskite type and pyrochlore type, and the former superconducting layer and the latter superconducting layer both have an RE123 composition. Accordingly, the critical current value can be improved. | 2009-09-24 |
20090239754 | COLD GAS SPRAYING METHOD - In a cold gas spraying method, a gas jet ( | 2009-09-24 |
20090239755 | Identification of Compounds Modifying A Cellular Response - The present invention relates to methods for identifying compounds capable of modulating a cellular response. The methods involve attaching living cells to solid supports comprising a library of test compounds. The test compounds are linked to the solid support via cleavable linkers and may thus be released from the solid supports. Solid supports comprising cells, wherein the cellular response of interest has been modulated are selected and the test compound of the solid support can then be identified. The cellular response may for example be changes in complex formation between proteins. | 2009-09-24 |
20090239756 | PREDICTORS FOR METASTASIS OF BREAST CANCER - There is provided a gene expression pattern which is clinically relevant to metastasizing breast cancer. In particular, the identity of genes that are correlated with patient survival and breast cancer recurrence are provided. The gene expression profile, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to predict survival of subjects afflicted with breast cancer and the likelihood of breast cancer recurrence. The invention thus provides for the use of a gene expression pattern (or profile or “signature”) which correlates with (and thus able to discriminate between) patients with good or poor survival outcomes. | 2009-09-24 |
20090239757 | Control Sequences Responding to AMP and Uses Thereof - The present invention relates to a method of identifying control sequences responding to antimicrobial peptides (AMPs), to host cells expressing an AMP and comprising a control sequence of the invention operable linked to a reporter, and to a method of screening for novel AMPs or AMP-variants having improved antimicrobial activity. Particularly the present invention relates to DNA control sequences, wherein the transcriptional profiles of said control sequences are regulated by the presence of an antimicrobial polypeptide expressed inside the host cell. | 2009-09-24 |
20090239758 | METHODS, MICROARRAY, AND KITS FOR DETECTION OF DRUG RESISTANCE GENES IN GRAM-NEGATIVE BACTERIA - The present invention provides kits and microarrays containing primer pairs for amplifying drug resistance genes and/or probes for detection of drug resistance genes. Also provided are methods of detecting drug resistance genes using kits and microarrays described herein. | 2009-09-24 |
20090239759 | MULTIPLEXED MOLECULAR ANALYSIS SYSTEMS - A method and apparatus for analyzing molecular structures within a sample substance using an array having a plurality of test sites upon which the sample substance is applied. The invention is also directed to a method and apparatus for constructing molecular arrays having a plurality of test sites. The invention allows for definitive high throughput analysis of multiple analytes in complex mixtures of sample substances. A combinatorial analysis process is described that results in the creation of an array of integrated chemical devices. These devices operate in parallel, each unit providing specific sets of data that, when taken as a whole, give a complete answer for a defined experiment. This approach is uniquely capable of rapidly providing a high density of information from limited amounts of sample in a cost-effective manner. | 2009-09-24 |
20090239760 | Method for the Identification of New Leads for Drug Candidates - Disclosed is a method for producing new leads for drug candidates. The method employs a combinatorial approach for identifying high affinity ligands. The target may be unknown and/or may include one or more unknown binding sites. A method involving a combined screening and synthesis method for bi-site inhibitors is disclosed comprising: 1) determining if there is sufficient proximity between ligands binding to different sites of a target: e.g. by using spin-labelled ligands quenching can be measured with NMR if a first ligand and second allosteric ligand are in proximity 2) connecting both ligands having linkers, via in situ synthesis in the presence of the protein scaffold (e.g. target guided synthesis combined with fragment based self assembly). Click chemistry is a preferred embodiment here. Also disclosed are kits used in context of this method, leads discovered by the method and their use in drug development. Leads for drugs acting on myelin associated glycoprotein (MAG) have been identified and synthesised. | 2009-09-24 |
20090239761 | Protein arrays and uses thereof - The inventors herein describe methods for the production of a functional human, animal, plant or microbe protein arrays and methods to assay for interactions between the proteins on the array with molecules of interest, for example, using such arrays to determine the in vitro metabolite profile of any drug. Such protein arrays can be used, for example, to assay, in a parallel fashion, the protein products of DNA sequences encoding drug metabolizing enzymes (DMES) to obtain a toxicology profile. Also described herein is a novel DME expression and purification strategy using detergents and not requiring an ultra-centrifugation step. | 2009-09-24 |
20090239762 | APTAMERS THAT BIND ABNORMAL CELLS - A new aptamer approach for the recognition of specific small cell lung cancer (SCLC) cell surface molecular markers relies on cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) to evolve aptamers for whole live cells that express a variety of surface markers representing molecular differences among cancer cells. When applied to different lung cancer cells including those from patient samples, these aptamers bind to SCLC cells with high affinity and specificity in different assay formats. When conjugated with magnetic and fluorescent nanoparticles, the aptamer nano-conjugates could effectively extract SCLC cells from mixed cell media for isolation, enrichment, and sensitive detection. | 2009-09-24 |
20090239763 | MARKERS FOR BREAST CANCER - Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described. | 2009-09-24 |
20090239764 | ARRAY-BASED TRANSLOCATION AND REARRANGEMENT ASSAYS - Methods for detecting genomic rearrangements are provided. In one embodiment, methods are provided for the use of paired end tags from restriction fragments to detect genomic rearrangements. Sequences from the ends of the fragments are brought together to form ditags and the ditags are detected. Combinations of ditags are detected by an on-chip sequencing strategy that is described herein, using inosine for de novo sequencing of short segments of DNA. In another aspect, translocations are identified by using target specific capture and analysis of the captured products on a tiling array. | 2009-09-24 |
20090239765 | GENES WHOSE EXPRESSION IS INCREASED IN RESPONSE TO STIMULATION BY CORTICOTROPIN-RELEASING HORMONE - The present invention relates generally to therapy and diagnosis of depression. In particular this invention relates to the polypeptides as well as to the polynucleotides encoding these polypeptides, wherein said polypeptides are shown to play a central role in mediating the endocrine response to corticotropin releasing hormone. These polypeptides and polynucleotides are useful in the diagnosis, treatment and/or prevention of depression. | 2009-09-24 |
20090239766 | METHOD FOR THE IDENTIFICATION OF HUMAN IMMUNODEFICIENCY VIRUS RELATED ANTIBODIES IN BLOOD - This invention discloses using SPR technology to simultaneously and qualitatively measure the presence of HIV related antibodies in a serum sample for the diagnosis of HIV infection. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of HIV related antigens used for the diagnosis of HIV infection. | 2009-09-24 |
20090239767 | BIOMOLECULE DETECTION REAGENT AND METHOD FOR DETECTING BIOMOLECULE USING REAGENT - A biomolecule detection reagent comprising semiconductor nanoparticles and magnetic nanoparticles, incorporated in a bead comprising an inorganic compound or an organic polymer, and a surface of the beads is modified with a biomolecule detection molecule. | 2009-09-24 |
20090239768 | METHOD FOR PREPARING COMPOUNDS BY NUCLEIC ACID DIRECTED SYNTHESIS - The present invention provides compositions, compounds and methods for in vitro DNA display technology, allowing display of a variety of molecules, in particular molecules obtained by water incompatible mechanisms. Advantages of such methods are that combinatorial libraries can be constructed comprising molecules which are obtained through water incompatible reactions. | 2009-09-24 |
20090239769 | Expression Miniarrays and Uses Thereof - The present invention provides methods and devices for making new and inexpensive miniarrays suitable for gene expression analysis. Also provided herein are methods of diagnosis for specific tissue or condition using specialized diagnostic miniarrays that exhibit specific visual pattern as diagnostic readout. | 2009-09-24 |
20090239770 | DETECTION OLIGOMER AND METHOD FOR CONTROLLING QUALITY OF BIOCHIP USING DETECTION OLIGOMER - A detection oligomer and method for controlling the quality of a biochip using the detection oligomer are provided. The detection oligomer includes a template having a first and second end and having a sequence that is complementary to a specific sequence of an oligomer, and a hairpin connected to the first end of the template. | 2009-09-24 |
20090239771 | Swelling Inhibitors for Clays and Shales - Method for inhibiting the hydration of clays and shales during drilling operations comprising the use of a water base drilling fluid, which contains from 0.2 to 5% by weight of the condensation product of a dicarboxylic acid having 4 to 10 carbon atoms with alkanolamines, diamines or polyalkyleneamines of formula R′″R″N—R′—XH, where X is O or NR | 2009-09-24 |
20090239772 | Method of producing a friction lining - The invention relates to a method of producing a friction lining whereby a friction paper is displaced with a latex based on an elastomer and fibers of the friction paper are then bonded one another due to precipitation of the elastomer out of the latex. A non-surface active protective colloid is added to the latex as a suspension agent before applying it to the friction paper. | 2009-09-24 |
20090239773 | LUBRICANT ADDITIVE, LUBRICANT COMPOSITION AND GREASE COMPOSITION - A lubricant additive comprising a rod-like liquid crystal compound possessing a cation group and an anion is disclosed. The rod-like liquid crystal compound is typically a specific type of 4-(1,3-diox-2-yl)pyridinium salt and exhibits an effect of reducing the coefficient of friction if added in a small amount. A lubricant composition and a grease composition comprising the lubricant additive are also disclosed. | 2009-09-24 |
20090239774 | LUBRICANTS FOR USE IN PROCESSING OF METALLIC MATERIAL AND METHODS FOR PROCESSING THE METALLIC MATERIAL USING THE LUBRICANTS - A nonchlorine lubricant for use in processing of a metallic material includes a lubricant base. The lubricant base includes at least one member selected from the group consisting of the vegetable oils and the neopentylated polyol esters. The lubricant may further include an additive added to the lubricant base. The additive comprises a sulfuric extreme pressure agent, an organozinc compound and a calcium ingredient. Preferably, the additive is added to the lubricant base such that sulfur content, zinc content and calcium content in the lubricant are respectively 5.0-50 wt %, 0.2-10 wt % and 0.01-10 wt % of total weight of the lubricant. | 2009-09-24 |
20090239775 | OPHTHALMIC SOLUTIONS DISPLAYING IMPROVED EFFICACY - The present invention relates to ophthalmic compositions comprising a pH between about 6 and about 8 and about 50 to about 1000 ppm hydrogen peroxide, about 100 ppm to about 2000 ppm of at least one chlorite compound and about 20 to 100 ppm of at least one saturated, polymeric quaternium salt. The ophthalmic compositions of the present invention display improved antifungal efficacy against | 2009-09-24 |
20090239776 | COMPOSTION INCORPORATING EMOLLIENT OILS INTO BODYWASH - Bodywash compositions incorporating high levels of emollient oils and a method for incorporating such high levels of emollient into bodywash compositions. | 2009-09-24 |
20090239777 | ANTIOXIDANTS FOR POST-CMP CLEANING FORMULATIONS - An cleaning composition and process for cleaning post-chemical mechanical polishing (CMP) residue and contaminants from a microelectronic device having said residue and contaminants thereon. The cleaning compositions include novel corrosion inhibitors. The composition achieves highly efficacious cleaning of the post-CMP residue and contaminant material from the surface of the microelectronic device without compromising the low-k dielectric material or the copper interconnect material. | 2009-09-24 |
20090239778 | Cleaning Agent - The invention relates to a combination product comprising a packaging means and two liquid washing or cleaning agents A and B of composition A, which are located in said packaging means while being separated from one another therein. Composition A consists of: 10 to 75% by weight of builder(s); 0.1 to 10% by weight of enzyme(s); 24.9 to 89.9% by weight of water, and composition B consists of: 10 to 74.9% by weight of builder(s); 25 to 89.9% by weight of water, and; 0.1 to 15% by weight of bleaching agent. The invention is characterized in that the liquid cleaning agent A has a pH value (20° C.) ranging from 6 to 9 and is characterized by having an improved cleaning efficiency compared to that of conventional solid or liquid dishwashing cleaning agents. | 2009-09-24 |
20090239779 | Laundry Detergent Composition Comprising the Magnesium Salt of Ethylene Diamine-N'N-Disuccinic Acid - The present invention relates to a solid laundry detergent composition comprising the magnesium salt of ethylene diamine-N′N′-disuccinic acid. | 2009-09-24 |
20090239780 | Detergent Composition Comprising Cellulosic Polymer - The present invention relates to a solid laundry detergent composition comprising a particle, wherein the particle comprises from 70 wt % to 100 wt % cellulosic polymer, and wherein the composition comprises silicate salt. | 2009-09-24 |
20090239781 | Detergent Composition Comprising a Co-Polyester of Dicarboxylic Acids and Diols - The present invention relates to a solid particulate laundry detergent composition comprising: (a) 0.1 wt % to 20 wt % detersive surfactant, wherein the surfactant comprises: (i) alkyl benzene sulphonate; and (ii) one or more detersive co-surfactants; (b) a co-polyester of dicarboxylic acids and diols; (c) polymeric carboxylate; (d) bleach; and (e) cellulosic polymer; wherein the composition comprises a spray-dried particle comprising at least some of the alkyl benzene sulphonate and at least some of the polymeric carboxylate, wherein the weight ratio of alkyl benzene sulphonate to repel-o-tex present in the composition is in the range of from 20:1 to 100:1, and wherein the weight ratio of detersive co-surfactant to repel-o-tex present in the composition is in the range of from 5:1 to 60:1. | 2009-09-24 |
20090239782 | High-molecular weight conjugate of resorcinol derivatives - Provided is a high-molecular weight conjugate of resorcinol derivatives which is excellent in water solubility and stability and has high antitumor activity even when used in a smaller total drug amount than the resorcinol derivatives. The high-molecular weight conjugate of resorcinol derivatives comprises a structure in which a carboxyl group of polymer moiety having a carboxyl group in the side chain and polyethylene glycol moiety is linked to a hydroxyl group of resorcinol derivatives via an ester bond. | 2009-09-24 |
20090239783 | SYNERGISTIC EFFECTS OF COMBINED ADMINISTRATION OF MIRTAZAPINE AND A STIMULANT COMPOUND - The invention discloses combination therapies and formulations of a stimulant (e.g., amphetamine) and mirtazapine and their methods of use. | 2009-09-24 |
20090239784 | Stablised Insulin Compositions - The present invention relates to human insulin analogues having a fast onset of action. These analogues may have amino acid in position B26 substituted with Phe, or be Des(B30) analogues of human insulin. The invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of an insulin analogue having a fast onset of action and insulin having a protracted action. | 2009-09-24 |
20090239785 | Insulin Derivative - The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to methods of providing such derivatives, to pharmaceutical compositions containing them, to methods of treating diabetes and hyperglycaemia using the insulin derivatives of the invention and to the use of such insulin derivatives in the treatment of diabetes and hyperglycaemia. | 2009-09-24 |
20090239786 | Novel Biomaterial Drug Delivery and Surface Modification Compositions - An antimicrobial coating is provided for use on textiles, medical devices, packaging materials, and the like. | 2009-09-24 |
20090239787 | SELF-FOAMING CEMENT FOR VOID FILLING AND/OR DELIVERY SYSTEMS - A self-foaming bone cement is described herein. In one variation, the bone cements include a self setting calcium phosphate cement formulation which when cured, forms macroscopic pores of varying sizes and densities with sufficient surface area to provide substantial regions for bone turnover. | 2009-09-24 |
20090239788 | RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS - The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others. | 2009-09-24 |
20090239789 | METHODS OF TREATMENT WITH DRUG LOADED POLYMERIC MATERIALS - Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered. | 2009-09-24 |
20090239790 | NOVEL RECOMBINANT PROTEINS WITH N-TERMINAL FREE THIOL - The present invention relates to novel modified proteins having N-terminal free thiols that can be produced by recombinant methods and are ready for further chemical derivatization. In particular, the invention relates to erythropoietin conjugate compounds having altered biochemical, physiochemical and pharmacokinetic properties. More particularly, one embodiment of the invention relates to erythropoietin conjugate compounds of the formula: | 2009-09-24 |
20090239791 | PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC SUBSTANCE WHICH INHIBITS IL-2 PRODUCTION - A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph following oral administration, is disclosed. The pharmaceutical composition can inhibit blood exposure of the substance to reduce its adverse effects, and can develop desired pharmacological effects. | 2009-09-24 |
20090239792 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms; and to a combination product comprising at least two such derivatives. The invention further relates to a method for sensitizing Gram-negative bacteria to an antibacterial agent by administering, simultaneously or sequentially in any order a therapeutically effective amount of said antibacterial agent and a derivative according to the present invention to said subject; to methods for developing novel antibiotics; and for sensitizing clinically important bacteria to a host defense mechanism complement present in serum. The invention also relates to a method of treating a subject for a gram-negative bacterial infection by administering a polymyxin derivative of the invention in combination with a second antibacterial agent. Finally, the invention relates to a process for preparing such polymyxin derivatives. | 2009-09-24 |
20090239793 | Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover - The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same. | 2009-09-24 |
20090239794 | HCV F PROTEIN AND USES THEREOF - The invention provides polypeptides, nucleic acids, antibodies, compositions, vaccines, microarrays and uses thereof for the prevention, treatment of HCV infection. The invention further provides uses of the above-noted products for the detection and diagnosis of HCV infection. The invention further provides corresponding methods and commercial packages relating to such uses. The invention further provides recombinant polypeptides and methods for their production. | 2009-09-24 |
20090239795 | EXENDIN FUSION PROTEINS - The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight. | 2009-09-24 |
20090239796 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT - Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA | 2009-09-24 |
20090239797 | PRODUCTION OF HIGH LEVELS OF TRANSGENIC FACTOR IX WITHOUT GENE RESCUE, AND ITS THERAPEUTIC USES - A non-human trangenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human FIX protein without the benefit of the presence of a complete milk gene sequence for gene rescue, and a signal sequence is active in directing newly expressed Factor IX into the milk of the animal at levels in an unactivated form that is suitable for subsequent processing for therapeutic applications in treating Hemophilia B. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. The applications include milk derivatives for oral delivery and oral tolerization in the treatment of Hemophilia B. | 2009-09-24 |
20090239798 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide - The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide. | 2009-09-24 |
20090239799 | Pharmaceutical Compositions Comprising Ccl2 and Use of Same For The Treatment of Inflammation - A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation. | 2009-09-24 |
20090239800 | CLC Channel Ligand - Compositions and methods of using scorpion venom peptide that is a ligand for ClC channels are provided. One aspect provides a pharmaceutical composition containing an amount of GaTx2 effective to inhibit ClC activity. Methods of treating a disorder or symptom of a disorder related to aberrant ClC channel activity are also provided. | 2009-09-24 |
20090239801 | Modified Fusion Polypeptides - Chimeric polypeptides wherein the polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of such modified growth hormone binding domains. | 2009-09-24 |
20090239802 | Hsp70 PEPTIDE STIMULATING NATURAL KILLER (NK) CELL ACTIVITY AND USES THEREOF - The present invention relates to an immunostimulatory peptide derived from an Hsp70 protein and peptides comprising said immunostimulatory peptide. Furthermore the present invention pertains to polynucleotides encoding said peptide, vectors comprising said polynucleotides, fusion (poly)peptides comprising said peptide and compositions comprising said peptide. In addition the present invention relates to the use of said peptide, polynucleotide, vector or fusion (poly)peptide, for the preparation of pharmaceutical compositions for the treatment of diseases and for the stimulation of natural killer cell (NK cell) activity. | 2009-09-24 |
20090239803 | BITE-SIZE CARBOHYDRATE NUTRITIONAL PRODUCTS AND METHODS FOR USING SAME - Bite-size carbohydrate-based products and methods of using same are provided. In a general embodiment, the present disclosure provides a bite-size carbohydrate-based product comprises a carbohydrate source comprising a glucogenic:fructogenic carbohydrate ratio ranging between about 1.5 to about 2.5 with at least 60% of the energy content of the bite-size carbohydrate-based product coming from the carbohydrate source. Along with the carbohydrate source, the bite-size carbohydrate-based product further comprises a suitable amount of sodium. The bite-size carbohydrate-based products can be specifically designed and provided to an athlete for customized carbohydrate intake and portion control before, during and/or after exercising. | 2009-09-24 |
20090239804 | PREVENTION AND TREATMENT OF OSTEOARTHRITIS - Subjects lacking Nfat1 display osteoarthritis in weight-bearing joints. Osteoarthritic changes associated with Nfat1 deficiency are characterized by articular cartilage degradation, articular chondrocyte proliferation/clustering, progressive articular surface destruction, periarticular chondro-osteophyte formation, and exposure of thickened subchondral bone. Methods of treating osteoarthritis, methods of diagnosis and early prediction of the onset of osteoarthritis, and methods for screening drug candidates that may be useful for treatment of osteoarthritis are presented. | 2009-09-24 |
20090239805 | HUMAN 3 RELAXIN - Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment of conditions responsive to administration of H3 relaxin or analogues thereof. | 2009-09-24 |
20090239806 | GLYPICAN-3 (GPC3)-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES USEFUL FOR HLA-A2-POSITIVE PATIENTS AND PHARMACEUTICAL COMPRISING THE SAME - It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B):
| 2009-09-24 |
20090239807 | Methods and kits for diagnosing and/or assessing severity and treating gaucher disease - Methods and kits for treating Gaucher disease are provided. The methods are based on using agents capable of inhibiting proteasomal degradation of glucocerebrosidase and/or elevating a level of mis-folded yet active glucocerebrosidase in cell lysosomes. Also provided are methods and kits for diagnosing and/or assessing a severity and determining prognosis of Gaucher disease or other diseases associated with abnormally folded proteins which are retained in the ER. | 2009-09-24 |
20090239808 | CALCIUM RECEPTOR ACTIVATOR - A calcium receptor activator and compositions containing at least one of the following: γ-Glu-Cys-Gly, γ-Glu-Cys(SNO)-Gly, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ-Glu-Met(O), γ-Glu-Val-Val, γ-Glu-Val-Glu, γ-Glu-Val-Lys, γ-Glu-γ-Glu-Val, γ-Glu-Val-NH | 2009-09-24 |
20090239809 | Process For Preparing Peptide Products For Promoting Cholecystokinin Secretion And Use Of The Peptide Products - A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof. | 2009-09-24 |
20090239810 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE - The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 2009-09-24 |
20090239811 | POLYCATIONIC COMPOUNDS AND USES THEREOF - Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis. | 2009-09-24 |
20090239812 | USE OF C7 SUGARS IN PREVENTION AND TREATMENT OF MYCOSES - The object of the invention is use of at least one C7 sugar to make a composition intended for prevention and/or treatment of mycoses selected from among the group constituted of candidoses and pityrosporoses. The C7 sugars are preferably a water soluble extract of avocado sugars. | 2009-09-24 |
20090239813 | Analogs of Alpha Galactosyceramide and Uses thereof - There are disclosed compound of formula I, in which R | 2009-09-24 |
20090239814 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides - The present invention provides iRNA agents comprising at least one subunit of the formula (I): | 2009-09-24 |
20090239815 | Novel human microRNAs associated with cancer - The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents. | 2009-09-24 |
20090239816 | Multitargeting Interfering RNAs And Methods Of Their Use And Design - Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are used to modulate expression of the target sequences. Such a multitargeting interfering RNA approach provides a powerful tool for gene regulation. | 2009-09-24 |
20090239817 | ORGANIC THIOPHOSPHATE ANTIRETROVIRAL AGENTS - A method for the prevention or treatment of human immunodeficiency virus infection by administering an effective amount of amifostine, phosphonol, or similar compound to an individual in need is provided. | 2009-09-24 |
20090239818 | EFFECTIVE TREATMENT OF OVARIAN CANCER USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. The invention further encompasses a number of miRNAs, which are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, -199a*, -200a, -100, -12Sb, and let-7 cluster. Further, the invention illustrates that frequent deregulation of miR-214, -199a*, -200a and -100 in ovarian cancers and their alterations are associated with high grade and late stage tumor. Significantly, miR-214 induces cell survival and cisplatin resistance through targeting 3′UTR of the PTEN, which leads to down regulation of PTEN protein and activation of Akt pathway. Inhibition of Akt using Akt inhibitor, API-2/triciribine, or introduction of PTEN cDNA lacking 3′UTR largely abrogates miR-214 induced cell survival. These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway. | 2009-09-24 |
20090239819 | PERITONEAL DIALYSIS SOLUTION TEST METHOD - A method of testing a glucose polymer or a glucose polymer derivative includes providing a sample of the glucose polymer or glucose polymer derivative. The sample is filtered at a specified molecular weight cutoff to obtain a retentate portion and a filtrate portion. The retentate portion is added to a first assay. The filtrate portion is added to a second assay. A reagent is added to each of the first assay and the second assay. The reagent produces a proinflammatory response. The proinflammatory response of each of the first assay and the second assay is measured. The proinflammatory response of the first assay is compared to the proinflammatory response of the second assay to determine if the glucose polymer or glucose polymer derivative is suitable for use in a patient. | 2009-09-24 |
20090239820 | Compounds and methods for treatment of solid tumors - The present invention relates to pharmaceutical compositions containing targetable bioconjugates of hydralazine, a direct vasodilating agent previously shown to decrease tumor blood flow, oxygenation and interstitial fluid pressure in solid tumors. These bioconjugates are hydralazine prodrugs that contain hydralazine conjugated to biocompatible carrier molecules which specifically bind to sites that are expressed on a diverse variety of tumor cell types. These hydralazine prodrugs are preferably conjugated through an acid-labile hydrazone link that is designed to be stable in plasma and release hydralazine through acid-catalyzed hydrolysis in the acidic environment of the target tumor. Because these prodrugs are stable at physiological pH and in plasma, they are devoid of systemic vasoactive activity; however, they are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor where the vasoactive activity of hydralazine is restored. These prodrugs selectively bind to tumor-specific receptors on tumor cells, and are degraded in the acidic tumor cell environment or the acidic lysosomal compartments after being internalized into the cell. | 2009-09-24 |
20090239821 | DESTRUCTION OF MICROBIAL PRODUCTS BY ENZYMATIC DIGESTION - Methods of treating a dialysis component by providing a dialysis component and contacting the dialysis component with an enzyme are provided. The enzyme breaks down microbial contaminants in the dialysis component. The enzyme may be separated from the dialysis component to provide a purified dialysis component. The purified dialysis component may be substantially free of microbial contaminants that cause a cytokine response in humans. | 2009-09-24 |
20090239822 | Process for the preparation of esters of diacerein with hyaluronic acid and pharmaceutical compositions containing such esters - A process is described for the preparation of esters of diacerein with hyaluronic acid by means of which stable products are obtained, which are practically free of impurities and characterized by a prolonged anti-inflammatory activity. Also described are pharmaceutical compositions containing said esters having prolonged anti-inflammatory activity and are suitable for intra-articular administration. | 2009-09-24 |
20090239823 | FOODS AND DRINKS HAVING HEALTH BENEFITS AND METHOD FOR ADDING HEALTH BENEFITS TO FOODS AND DRINKS - A method for controlling intestinal function, blood sugar level, body fat or serum lipid, or maintaining and improving glucose tolerance. The method comprises giving to human body or animal foods and drinks, having health benefits, or enriched with health benefits, wherein the foods and drinks comprise as an active ingredient a hydrogenated, indigestible dextrin that is obtained by digesting pyrodextrin with an enzyme to obtain an indigestible dextrin, and then hydrogenating the indigestible dextrin. | 2009-09-24 |